<DOC>
	<DOCNO>NCT00704262</DOCNO>
	<brief_summary>There therapy suitable treatment psoriasis face skin fold . As area sensitive , irritation adverse reaction common elsewhere body . The purpose study monitor effect daily treatment 8 week ointment contain calcipotriol 25 mcg/g plus hydrocortisone 10 mg/g hypothalamic-pituitary-adrenal axis calcium metabolism patient psoriasis vulgaris face intertriginous area</brief_summary>
	<brief_title>Effect Calcipotriol Plus Hydrocortisone Ointment Adrenal Hormone Balance Calcium Metabolism Patients With Psoriasis Vulgaris Face Skin Folds</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>Clinical diagnosis psoriasis vulgaris involve face intertriginou area Clinical diagnosis psoriasis vulgaris trunk and/or limb earlier diagnosed psoriasis vulgaris trunk and/or limbs An extent psoriatic involvement face least 5 cm2 sum facial intertriginous lesion least 30 cm2 Treatment area ( face intertriginous ) amenable topical treatment maximum 100g ointment per week Disease severity face intertriginous area grade moderate , severe severe accord investigator´s global assessment disease severity Patients normal HPA axis function : serum cortisol concentration 5 mcg/dl ACTH ( tetracosactid/cosyntropin ) injection serum corticol concentration 18 mcg/dl 30 min ATCT ( tetracosactid/cosyntropin ) injection Albumin correct serum calcium within reference range Females childbearing potential use highly effective method contraception study ( hormonal contraceptive oestrogen basis allow ) A history active allergy , asthma , allergic skin rash , sensitivity medication ( include ACTH/tetracosactid/cosyntropin ) component formulation test Systemic treatment therapy biologicals , potential effect psoriasis vulgaris ( eg vitamin D analogue , retinoids ) within 2 week prior Visit 1 . Stable treatment methotrexate fumaric acid allow Systemic treatment corticosteroid within 12 week prior Visit 1 Systemic use biological treatment , whether market , direct potential effect psoriasis vulgaris ( eg . alefacept , efalizumab , etanercept , infliximab , adalimumab ) within 12 week prior Visit 1 PUVA therapy Grenz ray therapy within 4 week prior Visit 1 UVB therapy within 2 week prior Visit 1 Topical treatment WHO group 2 , 3 4 corticosteroid within 4 week prior Visit 1 Topical treatment WHO group 1 corticosteroid within 2 week prior Visit 1 Any topical treatment face intertriginous area ( except emollient ) within 2 week prior Visit 1 Oestrogen therapy medication know affect cortisol level HPAaxis integrity within 4 week prior Visit 1 Enzymatic inductor , systemic topical cytochrome P450 inhibitor , hypoglycaemic sulfonamide antidepressive medication within 4 week prior Visit 1 Current diagnosis erythrodermic , exfoliative , guttate pustular psoriasis Patients follow condition present treatment area : viral ( e.g. , herpes varicella ) lesion skin , fungal bacterial skin infection , parasitic infection , skin manifestation relation syphilis tuberculosis , rosacea , perioral dermatitis , acne vulgaris , atrophic skin , stria atrophicae , fragility skin vein , ichthyosis , acne rosacea , ulcer wound Other inflammatory skin disease ( e.g. , seborrhoiec dermatitis , contact dermatitis cutaneous mycosis ) may confound evaluation psorisis vulgaris face intertriginous area Planned exposure sun , UVA UVB study may affect psoriasis vulgaris Clinical sign symptom Cushing´s disease Addison 's disease Known suspect severe renal insufficiency severe hepatic disorder Known suspected disorder calcium metabolism associate hypercalcaemia Known suspect endocrine disorder may affect result ACTH challenge test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>